InflaRx N : Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19 - Form 6-K
IFRX
Disclaimer
Inflarx NV published this content on 12 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2021 11:41:02 UTC.